SCHEMBL4746063

SCHEMBL4746063

Cc1ccc2c(c1)c(-c1ccc3ccncc3c1)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.38
PIK3CB P42338 3/20 0.38
PIK3CG P48736 3/20 0.38
ABL1 P00519 5/20 0.36
TDO2 P48775 2/20 0.36
PRKCI P41743 1/20 0.36
KDR P35968 3/20 0.35
EGFR P00533 2/20 0.35
HCK P08631 2/20 0.35
SRC P12931 2/20 0.35
PIK3CA P42336 2/20 0.35
MTOR P42345 2/20 0.35
EPHB4 P54760 2/20 0.35
PRKDC P78527 2/20 0.35
LCK P06239 1/20 0.35
CSF1R P07333 1/20 0.35
MAPK14 Q16539 1/20 0.35
PRKCZ Q05513 1/20 0.34
F9 P00740 1/20 0.33
WNT1 P04628 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746099 0.96 ABL1 (0.36) PIK3CDPIK3CBPIK3CGABL1TDO2
SCHEMBL4746387 0.92 DHODH (0.33) KDM4EALDH1A1NPC1RAB9ALMNA
SCHEMBL4746389 0.91 DHODH (0.34) ABL1KDM4EALDH1A1NPC1RAB9A
SCHEMBL4745812 0.90 ALDH1A1 (0.34) PIK3CDPIK3CBPIK3CGABL1KDR
SCHEMBL13320366 0.88 TDO2 (0.41) PIK3CDPIK3CBPIK3CGABL1TDO2
SCHEMBL4746339 0.87 DHODH (0.36) MAPTKDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL4746317 0.86 DHODH (0.35) MAPTKDM4EALDH1A1KMT2ANPC1
SCHEMBL4746018 0.85 ALDH1A1 (0.44) PIK3CDPIK3CBPIK3CGABL1KDR
SCHEMBL4746019 0.85 ALDH1A1 (0.44) MAPK14ALDH1A1KMT2AMEN1
SCHEMBL4746310 0.85 BCHE (0.34) ABL1KDRLCKCSF1RMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 PIK3CD 2375/4885PIK3CB 3297/4885PIK3CG 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.